Frank Mottola Sells 15,000 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Stock

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) SVP Frank Mottola sold 15,000 shares of the stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $36.98, for a total transaction of $554,700.00. Following the completion of the sale, the senior vice president now directly owns 8,200 shares of the company’s stock, valued at $303,236. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Supernus Pharmaceuticals Trading Up 0.5 %

SUPN stock opened at $36.60 on Friday. The firm has a 50 day simple moving average of $33.13 and a 200-day simple moving average of $30.68. The company has a market capitalization of $2.02 billion, a P/E ratio of 34.21 and a beta of 0.86. Supernus Pharmaceuticals, Inc. has a twelve month low of $24.46 and a twelve month high of $39.37.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its quarterly earnings data on Monday, November 4th. The specialty pharmaceutical company reported $0.69 earnings per share for the quarter, topping the consensus estimate of $0.44 by $0.25. The company had revenue of $175.70 million during the quarter, compared to analyst estimates of $157.35 million. Supernus Pharmaceuticals had a net margin of 9.16% and a return on equity of 7.79%. The firm’s revenue for the quarter was up 14.2% compared to the same quarter last year. During the same period last year, the business earned ($0.29) EPS. On average, research analysts predict that Supernus Pharmaceuticals, Inc. will post 1.53 EPS for the current year.

Institutional Trading of Supernus Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the company. GAMMA Investing LLC lifted its holdings in Supernus Pharmaceuticals by 97.1% during the 3rd quarter. GAMMA Investing LLC now owns 808 shares of the specialty pharmaceutical company’s stock worth $25,000 after buying an additional 398 shares during the last quarter. EntryPoint Capital LLC bought a new position in Supernus Pharmaceuticals during the first quarter worth $43,000. Meeder Asset Management Inc. bought a new stake in Supernus Pharmaceuticals during the second quarter valued at $47,000. Innealta Capital LLC acquired a new stake in shares of Supernus Pharmaceuticals during the second quarter worth $51,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Supernus Pharmaceuticals by 21.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,993 shares of the specialty pharmaceutical company’s stock worth $61,000 after buying an additional 352 shares during the last quarter.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the stock. StockNews.com upgraded shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. Piper Sandler reissued a “neutral” rating on shares of Supernus Pharmaceuticals in a research report on Friday, October 18th. Finally, Cowen reaffirmed a “buy” rating on shares of Supernus Pharmaceuticals in a research report on Friday, October 18th.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.